Drug
Cendakimab clinical trials
Also written CC-93538 and BMS-986355.
- studies test it
- 11
- open now
- 0
- in phase 3
- 3
- first study started
- 2009
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2014 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 2
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses cendakimab is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic GastroenteritisCompletedPhase 3CelgeneNCT05214768Written as CC-93538
- Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisCompletedPhase 3CelgeneNCT04991935Written as CC-93538
- A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic EsophagitisCompletedPhase 3CelgeneNCT04753697Written as CC-93538
- A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving CendakimabCompletedPhase 1CelgeneNCT05175352Written as Cendakimab
- A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic DermatitisCompletedPhase 2CelgeneNCT04800315Written as CC-93538
- A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05638282Written as Cendakimab
- A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05337345Written as Cendakimab
- Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult SubjectsCompletedPhase 1CelgeneNCT04373187Written as CC-93538
- Japanese Pharmacokinetic Bridging Study for CC-93538CompletedPhase 1CelgeneNCT04096105Written as CC-93538
- Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With AsthmaCompletedPhase 1AbbVieNCT00986037Written as ABT-308
- Dose Ranging Study of RPC4046 in Eosinophilic EsophagitisCompletedPhase 2CelgeneNCT02098473Written as RPC4046
Codes
What other systems call cendakimab · ClinicalTrials.gg INT000844
- MeSH (NLM) C000625155cendakimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) O8R9U9ZUVNCENDAKIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q123907243cendakimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174792CendakimabOne source FDA
- DrugBank DB18427One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000625155 | cendakimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | O8R9U9ZUVN | CENDAKIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123907243 | cendakimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174792 | Cendakimab | One source FDA |
| DrugBank | DB18427 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.